Inspired by the successful television series, the UCL School of Pharmacy has organised this clever and well-attended event where UCL scientists presented their small molecule therapeutics idea to a panel of seasoned pharma experts and investors, in front of a public of scientists and company representatives. We couldn’t resist the temptation to pitch our Virology Research Services, and although VRS is not quite a small molecule, it was clearly exciting enough to win the third prize from the public! Thank you!
Recents Posts
New to Our Assay Portfolio: HSV-1 and HSV-2
VRS now offers antiviral testing services for alpha herpesviruses HSV-1 and HSV-2. Most people (60–65%) will be infected with HSV-1 over their lifetime, and HSV-2 infection is present in around 10–11%. Once considered little more than a benign nuisance, herpes simplex...
VRS Maintains ISO 17025: Regulatory-Ready Antiviral Testing
Regulatory testing requires data that's traceable, defensible, and meets internationally recognized standards. For product claims and regulatory submissions, results need to be backed by documented technical competence. ISO 17025 is the international standard for...
Viral contributions to evolution, genetic exchange, and ecology
Around 8% of the human genome consists of sequences derived from ancient retroviruses – infections that became permanently embedded in our ancestors' DNA millions of years ago. Most of these have since degraded or been silenced. But some have been repurposed, co-opted...
When it comes to viruses, we know our stuff!
Subscribe


